Shareholder Vote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 23, 2026 PFIZER INC . (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Identification No.) incorporation)     66 Hudson Boulevard East 10001-2192 New York, New York (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 212 ) 733-2323 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.05 par value PFE New York Stock Exchange 1.000% Notes due 2027 PFE/27 New York Stock Exchange 2.875% Notes due 2029 PFE/29 New York Stock Exchange 3.250% Notes due 2032 PFE/32 New York Stock Exchange 3.875% Notes due 2037 PFE/37A New York Stock Exchange 4.250% Notes due 2045 PFE/45 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐ Item 5.07 Submission of Matters to a Vote of Security Holders (a) The Pfizer Inc. (the "Company") Annual Meeting of Shareholders was held on April 23, 2026. (b) Shareholders voted on the matters set forth below. 1. The nominees for election to the Company’s Board of Directors set forth in Item 1 to the Company’s Proxy Statement filed with the U.S. Securities and Exchange Commission on March 12, 2026 were elected to hold office until the Company’s next Annual Meeting of Shareholders, based upon the following votes: Nominee Votes For       Votes Against Abstentions Broker non-vote Ronald E. Blaylock 3,442,653,662 102,600,748 11,374,500 941,392,137 Albert Bourla 3,261,211,737 272,132,573 23,284,563 941,392,137 Mortimer J. Buckley 3,403,974,675 141,036,932 11,617,303 941,392,137 Susan Desmond-Hellmann 3,401,932,807 141,056,147 13,639,956 941,392,137 Joseph J. Echevarria 2,929,511,380 612,413,502 14,702,274 941,392,137 Scott Gottlieb 3,415,886,776 130,394,185 10,343,738 941,392,137 Dan R. Littman 3,383,769,589 161,740,872 11,118,449 941,392,137 Shantanu Narayen 3,313,318,763 231,613,932 11,695,915 941,392,137 Suzanne Nora Johnson 3,272,936,863 273,506,151 10,185,896 941,392,137 James Quincey 3,453,778,741 91,549,236 11,300,933 941,392,137 James C. Smith 3,284,035,682 261,217,699 11,375,529 941,392,137 Cyrus Taraporevala 3,468,177,423 76,665,721 11,785,766 941,392,137 2. The proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year was approved based upon the following votes: Votes for approval 4,160,827,231 Votes against 321,979,096 Abstentions 15,214,720 Broker non-votes n/a 3. The proposal to approve the Pfizer Inc. 2019 Stock Plan, as amended April 2026 was approved based upon the following votes: Votes for approval 3,227,692,578 Votes against 305,428,376 Abstentions 23,507,956 Broker non-votes 941,392,137 4. The proposal to approve, on an advisory basis, the 2026 compensation of the Company's Named Executive Officers was approved based upon the following votes: Votes for approval 3,099,249,442 Votes against 423,935,881 Abstentions 33,443,287 Broker non-votes 941,392,137 5. The shareholder proposal to Adopt Adopt An Independent Chair Policy was not approved based upon the following votes: Votes for approval 1,015,206,372 Votes against 2,509,042,021 Abstentions 32,354,566 Broker non-votes 941,392,137 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   PFIZER INC.             Dated: April 27, 2026 By: /s/ Margaret M. Madden   Margaret M. Madden     Senior Vice President and Corporate Secretary     Chief Governance Counsel